Special Populations & SUDEP
Special Populations & SUDEP
What You'll Learn
- VPA is the highest-risk ASM in pregnancy: MCM 10.3%, IQ ↓7–10 points (NEAD), ↑ autism. Per 2024 AAN guidance: avoid in PWECP whenever possible; use only when benefits clearly outweigh risks AND alternative ASMs are inadequate
- Safest ASMs in pregnancy: LTG (2.3–2.9%), LEV (2.4–2.8%), OXC (≤3%); LTG clearance ↑50–100% — monthly levels, target ≥65% preconception
- Elderly = HIGHEST epilepsy incidence (130–140/100,000/yr); stroke most common cause (30–50%); “start low, go slow” with LTG, LEV, or lacosamide
- SUDEP strongest risk factor: ≥3 GTCS/yr (OR 15–23); MORTEMUS: GTCS → PGES → apnea → asystole (respiratory BEFORE cardiac)
- SUDEP prevention: seizure control most important; surgery ↓ risk 80–90%; nocturnal supervision ↓ risk 50–70%
- AAN 2017 (Level B): clinicians SHOULD inform patients about SUDEP; <10% currently receive counseling
HighYield Pearls
- AVOID valproate in PWECP: highest MCM (10.3%), NTDs, IQ ↓7–10 pts (NEAD), ↑ autism — 2024 AAN/AES/SMFM: avoid VPA in PWECP if clinically feasible; use only when expected benefits clearly outweigh risks and alternatives are inadequate
- AVOID topiramate in pregnancy: oral clefts (OR 5.4), SGA infants — if unavoidable, use lowest dose
- Safest ASMs in pregnancy: lamotrigine + levetiracetam (MCM 2.3–2.9%) — NAAPR/EURAP-supported
- LTG clearance ↑50–100% in pregnancy: monthly levels, target ≥65% of preconception — taper postpartum within days to avoid toxicity
- Enzyme-inducing ASMs (CBZ/PHT/PB/PRM, TPM ≥200, OXC ≥1500, ESL) ↓ OCP efficacy: use LNG-IUD or copper IUD — OCPs also ↓ LTG levels 40–60%
- SUDEP #1 risk factor: ≥3 GTCS/yr (OR 15–23); refractory GTCS, nocturnal/unwitnessed seizures, missed AED doses
- SUDEP mechanism (MORTEMUS): GTCS → PGES → central apnea → asystole (respiratory BEFORE cardiac collapse)
- SUDEP prevention: seizure control is paramount; epilepsy surgery ↓ risk 80–90%; nocturnal supervision ↓ risk 50–70%; VNS may help
- AAN 2017 Level B: counsel ALL PWE about SUDEP at diagnosis — currently <10% receive counseling
- Elderly = highest epilepsy incidence (130–140/100k/yr); stroke is #1 cause (30–50%) — LTG/LEV/lacosamide preferred; avoid IV PHT load (cardiac), TPM (cognitive)
🔍 Quick ReferencePregnancy / contraception · Special populations · SUDEP
Pregnancy / contraception
- Valproate in pregnancy → MCM 10.3%, NTDs, IQ ↓7–10 pts, autism — 2024 AAN: avoid whenever possible
- Topiramate + oral cleft → OR 5.4; also SGA infants (18.5%)
- Lamotrigine clearance ↑50–100% → estrogen-induced glucuronidation — monthly levels, target ≥65% preconception
- Postpartum LTG toxicity → taper increases over 2–3 wk; symptoms within days of delivery
- Enzyme-inducing ASM + OCP → contraceptive failure — choose LNG-IUD or copper IUD
- OCP + lamotrigine → estrogen ↓ LTG 40–60% (active weeks; rebound on placebo)
- Catamenial epilepsy → perimenstrual seizure exacerbation — cyclic acetazolamide, clobazam, progesterone trials
- Folic acid 0.4 mg/d minimum → 2024 AAN: insufficient evidence for routine 4 mg; higher dose case-by-case (VPA, prior NTD)
- Newborn vitamin K 1 mg IM → standard for all; maternal supplementation no longer routinely recommended (2024 AAN)
- Seizure freedom ≥9 mo preconception → 84–92% remain seizure-free in pregnancy
Special populations
- Elderly new-onset epilepsy → stroke #1 cause (30–50%); use LTG/LEV/lacosamide; “start low, go slow”
- IV phenytoin in elderly → avoid — cardiac dysrhythmia, hypotension
- Topiramate in elderly → avoid — cognitive slowing, word-finding
- Levetiracetam behavioral SE → irritability, aggression, depression — pyridoxine (B6) may mitigate
- Perampanel boxed warning → serious psychiatric/behavioral reactions (homicidal/suicidal ideation)
- Mood-stabilizing ASMs → CBZ, VPA, LTG — helpful in comorbid bipolar
- PNES + epilepsy comorbidity → 10–20% of PWE; treat PNES with CBT and multidisciplinary approach
- Intellectual disability + epilepsy → behavioral changes may mimic seizures; nocturnal pulse oximetry, safety counseling
- End-of-life seizures → buccal/intranasal/subcutaneous midazolam; deprescribe slowly
SUDEP risk / prevention
- SUDEP definition → sudden, unexpected, non-traumatic, non-drowning death in PWE; post-mortem non-specific; often in sleep
- SUDEP incidence → 1.16/1000 person-yr overall; ~10× higher in drug-resistant epilepsy
- SUDEP #1 risk factor → ≥3 GTCS/yr (OR 15–23)
- MORTEMUS sequence → GTCS → PGES → central apnea → asystole (respiratory failure precedes cardiac)
- Nocturnal/unwitnessed seizures, prone position → strong SUDEP risk — supine sleep + room-sharing protective
- Missed AED doses, subtherapeutic levels, alcohol → modifiable SUDEP risk factors
- Epilepsy surgery → ↓ SUDEP risk 80–90% in surgical candidates — refer early
- VNS for refractory epilepsy → may reduce SUDEP risk in long-term cohorts
- Seizure detection devices (SmartWatch, mattress sensors) → emerging; not proven to ↓ SUDEP mortality
- AAN/AES 2017 (Level B) → counsel ALL PWE about SUDEP at diagnosis
Women & Epilepsy: Pregnancy
Teratogenicity Ranking (EURAP / NAAPR Data)
| ASM | MCM Rate | Key Malformations | Dose-Dependent |
|---|---|---|---|
| Valproate | 10.3% | NTDs (1–2%), cardiac, hypospadias, cleft palate | Strong (>600–700 mg/d) |
| Phenobarbital | 6.5% | Cardiac defects, cleft lip/palate | Yes |
| Phenytoin | 6.4% | Cardiac, cleft lip/palate, fetal hydantoin syndrome | Moderate |
| Carbamazepine | 5.5% | NTDs (0.5–1%), cardiac | Yes (>400 mg/d) |
| Topiramate | ~3.9–4.3% | Oral clefts (OR 5.4), SGA (18.5%) | Moderate |
| Oxcarbazepine | ≤3% | No specific pattern | Limited data |
| Lamotrigine | 2.3–2.9% | No specific pattern | Weak (>300 mg/d) |
| Levetiracetam | 2.4–2.8% | No specific pattern | Not demonstrated |
2024 AAN/AES/SMFM Valproate Guidance
- Avoid valproic acid in PWECP if clinically feasible; use only when expected benefits clearly outweigh risks and alternative ASMs are inadequate
- If VPA is the only option → lowest effective dose (<600–700 mg/d when possible) with informed counseling on MCM, NTD, and neurodevelopmental risks
VPA Neurodevelopmental Effects (NEAD Study)
- IQ ↓7–10 points at ages 3, 4.5, 6 — dose-dependent
- ↑ Autism risk; impaired learning, memory, adaptive functioning
- Folic acid partially mitigates cognitive effects
VPA Reproductive Effects (PCOS / Fertility)
- VPA associated with PCOS features, hyperandrogenism, ↓AMH, and reduced fertility — additional reason to avoid in reproductive-age women
Pharmacokinetic Changes in Pregnancy
| ASM | Clearance Change | Mechanism | Monitoring |
|---|---|---|---|
| LTG | ↑ 50–100% | Estrogen-induced glucuronidation | Monthly levels; target ≥65% preconception |
| LEV | ↑ 40–60% | Increased renal clearance | Each trimester |
| OXC | ↑ 30–50% | Glucuronidation + renal | Each trimester |
| CBZ / VPA | Minimal change | Autoinduction (CBZ); ↓ protein binding (VPA) | Free VPA levels preferred |
- Postpartum: taper dose increases over 2–3 weeks — LTG toxicity risk within days of delivery
- Seizure freedom ≥9 months preconception → 84–92% chance remaining seizure-free
Folic Acid & Vitamin K
- 2024 AAN/AES/SMFM guideline: minimum at least 0.4 mg/day for all PWECP, including those on valproate. Higher doses (1–4 mg) are specialist-guided rather than evidence-proven — consider case-by-case (VPA exposure, prior NTD); evidence does not establish a routine high-dose (4 mg) folate recommendation.
- All newborns: vitamin K 1 mg IM at birth (standard). Per 2024 AAN guideline, maternal vitamin K supplementation is no longer routinely recommended
Key Registries
| Registry | Key Contribution |
|---|---|
| EURAP | Comparative MCM rates; dose-dependence |
| NAAPR | Specific MCM rates; TPM cleft signal |
| MONEAD | Seizure frequency; PK changes; breastfeeding |
| NEAD | VPA cognitive effects; IQ reduction; folic acid benefit |
Contraception
ASM–Contraceptive Interactions
| ASM Category | Specific ASMs | Effect | Best Contraceptive |
|---|---|---|---|
| Strong inducers | CBZ, PHT, PB, primidone | ↓↓ Estrogen & progestin | LNG-IUD or copper IUD |
| Moderate inducers | TPM ≥200 mg, OXC ≥1500 mg, ESL, clobazam | ↓ Estrogen & progestin | LNG-IUD; avoid OCPs |
| Non-inducing | LTG, LEV, LCM, VPA, GBP, PGB, ZNS, BRV | No effect | Any method |
- LNG-IUD (Mirena): best option on enzyme inducers — local action, not affected by hepatic induction
- Estrogen-containing OCPs ↓ LTG levels 40–60% (active pill weeks; rebound on placebo week)
- Emergency contraception: copper IUD most reliable regardless of ASM
Continue reading — sign in
The full note has more clinical pearls, tables, and board-focused tips. Free account, no fee.